WAVE is advancing a diverse pipeline of stereopure nucleic acid therapeutics across a broad spectrum of rare genetic diseases. Uniquely versatile, our technology can potentially be applied to develop drugs in multiple therapeutic areas utilizing any oligonucleotide therapeutic platform, including antisense, RNAi and exon-skipping, among others.
The chart below depicts our development plans as of January 2017. Our core goal is to initiate six clinical programs by 2018. We are currently supporting this goal with over 20 discovery programs that are focused on identifying candidate leads. While we do not anticipate that all of our candidate selection efforts will result in the identification of viable candidates nor that each candidate we select will necessarily advance to an IND filing and further development, our strategy is to maintain a pipeline that provides multiple opportunities for clinical and commercial success and demonstrates the breadth of our abilities across multiple organ systems and tissues and therapeutic modalities.
This chart contains forward-looking statements.